Lorlatinib - Pfizer
Alternative Names: [14C]Lorlatinib; LORBRENA; LORVIQUA; Lorviqua; PF-06463922; PF-6463922Latest Information Update: 13 Jul 2024
At a glance
- Originator Pfizer
- Developer CStone Pharmaceuticals; New Approaches to Neuroblastoma Therapy Consortium; Pfizer; The EVAN Foundation; University of Southern California
- Class Antineoplastics; Aza compounds; Benzoxazines; Nitriles; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase I Neuroblastoma
Most Recent Events
- 31 May 2024 Updated efficacy and adverse events data from a phase III CROWN trial in Non-small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Updated efficacy and adverse event data from the phase III CROWN trial in Non-small cell lung cancer released by Pfizer
- 13 Dec 2023 SCRI Development Innovations in collaboration with Pfizer withdraws a phase II trial prior to enrollment in Non-small cell lung cancer (Late-stage disease, Second-line therpay or greater) in USA due to pharmaceutical funding partners decision (NCT05948462)